NMN (Nicotinamide Mononucleotide)

NMN (Nicotinamide Mononucleotide) is a naturally occurring nucleotide derivative and direct biosynthetic precursor to NAD+ (nicotinamide adenine dinucleotide). It is found in small amounts in foods such as edamame, broccoli, avocado, and tomatoes, and is produced endogenously via the salvage pathway from nicotinamide.

The rationale for NMN supplementation comes from the established decline in NAD+ levels with aging across multiple species including humans, and the critical role NAD+ plays in mitochondrial energy production, DNA damage repair (via PARP enzymes), and sirtuin-mediated regulation of gene expression and cellular metabolism.

Unlike niacin or niacinamide, NMN enters the NAD+ biosynthesis pathway at a point closer to NAD+ itself — it is one enzymatic step away via NMNAT enzymes (NMN → NAD+). This distinguishes it from NR (nicotinamide riboside), which requires two steps (NR → NMN → NAD+).

Key human research milestones include a 2021 Cell Metabolism study (Yoshino et al.) demonstrating that 250 mg/day NMN for 10 weeks improved skeletal muscle insulin signaling and related gene expression in postmenopausal prediabetic women. A 2022 study reported reduced biological age scores over 60 days at 600 mg/day.

Animal studies show even more dramatic results: NMN reverses age-associated physiological decline in mice, restoring vascular function, muscle endurance, bone density, and energy metabolism. Translating these findings to humans remains an active area of research.

NMN works in concert with the entire NAD+ ecosystem — including SIRT1/SIRT3/SIRT5 sirtuins, PARP1/2/3 enzymes, CD38, and the mitochondrial electron transport chain — making it a broad-spectrum research tool for metabolic aging, neurodegeneration, cardiovascular disease, and longevity research.